5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer.
about
5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancerSimultaneous HPLC determination of 5-fluorouracil and its metabolites in plasma of cancer patients.Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel.Therapeutic drug monitoring of antimetabolic cytotoxic drugs.DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer.Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes.Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6.The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil.Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs.Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.The relevance of therapeutic drug monitoring in plasma and erythrocytes in anti-cancer drug treatment.No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusionPopulation pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenRelationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy.How may anticancer chemotherapy with fluorouracil be individualised?A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracilTherapeutic drug monitoring of cancer chemotherapy.Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients.Pharmacogenomics of fluorouracil -based chemotherapy toxicity.Therapeutic drug monitoring of 5-fluorouracil.Limited-sampling models for anticancer agents.The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy.An APCI LC-MS/MS method for routine determination of capecitabine and its metabolites in human plasma.Pharmacodynamic profile of prolonged etoposide administration in patients with small cell lung cancer and non-Hodgkin's lymphoma.Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy.Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy.[The acute toxicity of the simultaneous radiochemotherapy of rectal carcinoma].Pharmacokinetic adaptation of 5-fluorouracil: where are we and where are we going?Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects.Dose calculation of anticancer drugs
P2860
Q28359288-53520060-D68A-4103-AFA7-0884516BBB4AQ30863244-ACEB1AC5-A399-4202-A1D1-8EA27FBE7660Q33581242-3BB2FC6E-DCC8-49C8-9CE3-9AD2A06CAA5FQ33586713-554649D2-D660-4C98-AF20-D978BBDC01A4Q34021526-B7DC6889-D5AA-4E16-AB46-4630C7D13BD7Q34070317-0D07BE73-35B0-4A8F-B020-607E9306B89AQ34216563-7866C714-B84A-4CF9-988B-7DEA08B46873Q34612932-2E168C27-5B8A-43E6-9E02-E365A59DFAA3Q34636318-AAAB0938-5207-4348-A63B-B2476AD41869Q34761260-A8F2A6FC-A1D8-4868-A710-CADB48E561B3Q35060593-391501A7-C150-4C49-95E5-87F7EDF231ABQ35825206-708B1E4F-099F-4056-895B-195D0D6EC1EBQ35970344-D20C9637-2984-41CD-A684-CB2E47500985Q35993200-176F8CEC-5D04-434A-BFA1-76B9B27EAB07Q36055317-3A7A27DA-BA88-4B58-A52A-B0712E850371Q36322918-D41B98DF-CB6E-4422-B309-0B6C6CACFEB5Q36388048-A2459759-4288-4946-9BE8-D78B1C91982AQ36486034-2B1415CF-6A1C-4F7D-ACA9-DC92D9310D73Q36619294-B5EC01FB-DF22-46D6-83A3-BDDB96F21874Q37018328-AFC9C276-74B1-425F-A8F5-55F7D9F1E3B0Q38104743-D081D317-F7BD-4032-B182-6DA46C3F3B66Q38387640-82C92943-A30F-4218-BEF8-CC359FCC0757Q38842633-9614E821-D2EF-428C-8F47-DAA08DBD5DA4Q40755248-BBBC0F3A-F101-4838-8A6F-549B2BD2DE1DQ40870134-5E395876-5777-4574-B850-B3C9F0DA6AF6Q43043391-1C690618-C938-43E3-A86A-A1C5D6209EA6Q45115898-96FC9F04-38A0-46C8-A093-F10FF0AA0FE3Q45148168-59A549B5-9542-4A1E-9344-35D548D137E7Q50863687-D0C32471-1641-4780-AFFF-AD93FF01DE87Q50936160-879767AB-8BDC-476D-B806-E45B31667D48Q51311106-F35F6E0E-3959-4A19-B241-9680C5325296Q53633283-752F46FB-2157-4265-A4EB-F393685C3A56Q56391087-9A3479AF-E1EC-440B-AB5A-CF08473D399D
P2860
5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
5-FU therapeutic monitoring wi ...... index in head and neck cancer.
@ast
5-FU therapeutic monitoring wi ...... index in head and neck cancer.
@en
type
label
5-FU therapeutic monitoring wi ...... index in head and neck cancer.
@ast
5-FU therapeutic monitoring wi ...... index in head and neck cancer.
@en
prefLabel
5-FU therapeutic monitoring wi ...... index in head and neck cancer.
@ast
5-FU therapeutic monitoring wi ...... index in head and neck cancer.
@en
P2093
P2860
P356
P1476
5-FU therapeutic monitoring wi ...... index in head and neck cancer.
@en
P2093
Schneider M
P2860
P2888
P304
P356
10.1038/BJC.1989.59
P407
P577
1989-02-01T00:00:00Z